胰岛素样生长因子及其结合蛋白与妊娠期高血压疾病的相关性研究

目的:研究妊娠期高血压疾病患者血清胰岛素样生长因子-1(IGF-1)、胰岛素样生长因子结合蛋白-1(IGFBP-1)的水平与病情程度及新生儿出生体重之间的关系。方法:采用放射免疫方法测定并比较38例妊娠期高血压疾病患者与38例正常血压妊娠妇女的血清IGF-1、IGFBP-1的水平。结果:子痫前期组IGF-1显著低于妊娠期高血压组和正常组,而IGFBP-1水平显著高于妊娠期高血压组和正常组;妊娠期高血压组与正常组间IGF-1、IGFBP-1的水平比较,差异均无统计学意义。IGF-1水平与收缩压、舒张压及平均动脉压呈显著负相关,与新生儿出生体重呈显著正相关,而IGFBP-1与收缩压、舒张压及平均动脉压呈显著正相关,与新生儿出生体重呈显著负相关。结论:妊娠期高血压疾病患者的发病及严重程度与IGF-1、IGFBP-1有明显的关系,IGF-1、IGFBP-1与胎儿的发育及新生儿出生体重有明显的相关性。     

重组人生长激素对特发性矮小症患儿胰岛素样生长因子-1、胰岛素样生长因子结合蛋白-3的影响

目的探讨重组人生长激素对特发性矮小症患儿胰岛素样生长因子-1 (IGF-1)、胰岛素样生长因子结合蛋白-3(IGFBP-3)的影响,为临床治疗提供依据。方法选取2018年1月-2019年6月在该院就诊的特发性矮小症患儿72例为研究对象。采用随机数表法分为观察组和对照组,每组各36例。对照组患儿采取常规治疗,观察组在常规治疗的基础上给予患儿重组人生长激素治疗。比较两组患儿治疗前与连续治疗6个月后胰岛素样生长因子-1 (IGF-1)、胰岛素样生长因子结合蛋白-3(IGFBP-3)、生长激素(GH)及碱性磷酸酶(ALP)的变化,记录两组患者治疗前后身高、体质量、身高增长量的差异,统计不良反应发生率。结果治疗后,两组患儿IGF-1、IGFBP-3水平均高于治疗前,且观察组显著高于对照组,差异均有统计学意义(均P<0. 05)。治疗后,两组患儿GH、ALP水平均高于治疗前,且观察组显著高于对照组,差异均有统计学意义(均P<0. 05)。治疗6个月后,两组患儿身高、体质量、身高增长量等基本指标均有所升高,且观察组显著高于对照组,差异均有统计学意义(均P<0. 05)。治疗后,观察组患儿不良反应总发生率显著低于对照组,差异有统计学意义(P<0. 05)。结论重组人生长激素治疗儿童特发性矮小症效果显著,能提高患儿IGF-1、IGFBP-3等血清胰岛素样生长因子水平,有效改善患儿的GH、ALP指标水平,降低不良反应发生情况,促进患儿骨骼发育的同时加快其生长能力,值得临床推广使用。     

亮氨酸改善盲肠结扎穿孔小鼠生长激素抵抗

目的:探讨盲肠结扎穿孔小鼠生长激素-胰岛素样生长因子-1(GH-IGF-1)轴的变化及亮氨酸的干预作用. 方法:将40只小鼠随机分为四组,每组10只.即正常对照组(Control组)、假手术组(Sham组)、盲肠结扎穿孔等渗盐水组(CLP-N组)和盲肠结扎穿孔亮氨酸组(CLP-L组).采用盲肠结扎穿孔法制作腹腔感染模型后,CLP-N组给予等渗盐水灌胃,CLP-L组给予亮氨酸灌胃,连续7d.第8天腹腔麻醉后取门静脉血,检测小鼠血清生长激素(GH)和胰岛素样生长因子-1(IGF-1)水平.同时测定小鼠肝组织生长激素受体(GHR)、IGF-1、胰岛素样生长因子结合蛋白-1(IGFBP-1)和胰岛素样生长因子结合蛋白-3(IGFBP-3)mRNA表达量. 结果:与Control组比,CLP-N组小鼠血清GH水平明显升高(P＜0.01)、而血清IGF-1水平急剧下降(P＜0.01),并且伴随着肝组织GHR和IGFBP-3 mRNA水平显著降低(P＜0.01)以及IGFBP-1 mRNA水平明显升高(P＜0.01);而CLP-L组小鼠血清GH水平明显升高(P＜0.01)、血清IGF-1水平轻微下降(P＜0.05)以及肝组织GHR、IGFBP-1和IGFBP-3 mRNA水平明显升高(P＜0.01). 结论:盲肠结扎穿孔小鼠存在获得性GH抵抗,亮氨酸可改善此现象.     

小于胎龄儿早期体质量增长速率与IGF-1、IGFBP-3分泌速率的相关性研究

目的探讨小于胎龄儿(SGA)早期体质量增长速率与血清胰岛素样生长因子-1(IGF-1)、胰岛素样生长因子结合蛋白-3(IGFBP-3)分泌速率的关系。方法选取2013年9月-2015年12月在该院出生并在新生儿科住院的新生儿64例,其中SGA32例(SGA组),适于胎龄儿(AGA)32例(AGA组)。分别于生后第3、7、30天早晨8∶00~9∶00喂奶前采血,同时测量并记录体质量,采用化学发光法进行血清IGF-1、IGFBP-3水平测定。结果与生后第3天比较,两组新生儿生后第7天体质量、血清中IGF-1、IGFBP-3水平均无明显上升(P0.05);至生后第30天时,SGA组体质量、血清中IGF-1、IGFBP-3水平明显低于AGA组(P0.05);AGA组生后第30天时血清中IGF-1、IGFBP-3分泌速率与体质量增长速率呈显著正相关,而SGA组生后第30天时血清中IGF-1、IGFBP-3分泌速率与体质量增长速率无明显依耐性特点。结论 SGA组生后早期IGF-1、IGFBP-3的分泌水平相对较低,且分泌速率无明显体质量增长依耐性特点。SGA生后早期更需要合理充分营养以及早期干预。     

IGF-Ⅰ、IGF-Ⅱ、IGFBP-1与妊娠期高血压疾病的相关性研究

目的研究妊娠期高血压疾病(hypertensive disorder complicating pregnancy,HDCP)与胰岛素样生长因子-Ⅰ(insulin-like growth factor-Ⅰ,IGF-Ⅰ)、胰岛素样生长因子-Ⅱ(insulin-like growth factor-Ⅱ,IGF-Ⅱ)、胰岛素样生长因子结合蛋白-1(insulin-like growth factor binding protein-1,IGFBP-1)的相关性,为HDCP的病因学研究提供理论依据。方法采用酶联免疫吸附法(enzyme linked immunosorbent assay,ELISA)检测脐血和羊水中IGF-Ⅰ、IGF-Ⅱ、IGFBP-1水平。正常孕妇16例(对照组),HDCP孕妇48例(研究组),其中妊娠期高血压17例,轻度子痫前期16例,重度子痫前期15例。结果研究组较对照组IGF-Ⅰ、IGF-Ⅱ水平均显著下降(P<0.05)、IGFBP-1水平显著升高(P<0.05);研究组内IGF-Ⅰ和IGF-Ⅱ水平随病情程度加重而降低、IGFBP-1水平随病情程度加重而升高,不同病情程度之间比较差异有统计学意义(P<0.05)。研究组IGF-Ⅰ和IGF-Ⅱ呈正相关,IGF-Ⅰ、IGF-Ⅱ均与IGFBP-1呈负相关(P<0.05)。结论IGF-Ⅰ、IGF-Ⅱ、IGFBP-1与HDCP的发生和病情严重程度密切相关。     

宫内生长迟缓儿血清GH、IGF-1、IGFBP-3和瘦素水平及临床意义

【目的】探讨宫内生长迟缓(intrauterine growth retarded,I UGR)新生儿血清生长激素(growth hormone,GH)、胰岛素样生长因子-1(insulin-like growth factor-1,IGF-1)、胰岛素样生长因子结合蛋白-3(insulin-like growth factorbinding protein-3,IGFBP-3)、瘦素的浓度水平及临床意义。【方法】选择出生48-72 h的I UGR新生儿62例和足月适于胎龄儿(appropriate for gestional age,AGA)37例与早产AGA36例,其中I UGR分为重度I UGR组(29例),轻度I U-GR组(33例)和足月小于胎龄儿(small for gestional age,SGA)32例与早产SGA30例;分别于上午9时抽取静脉血,分离血清。采用放射免疫法测定GH、IGF-1、IGFBP-3和瘦素。【结果】①足月SGA和足月AGA组血清GH、IGF-1、IGFBP-3、瘦素浓度(μg/L)分别为6.58±1.42和24.32±3.59,11.89±3.01和37.12±6.4,82.3±19.66和256.55±33.62,2.75±0.66和7.58±1.26;早产SGA和早产AGA组血清GH、IGF-1、IGFBP-3、瘦素浓度(μg/L)分别为8.18±2.55和13.83±3.98,13.59±4.83和21.05±3.44,93.48±16.44和157.33±39.34,3.21±0.61和4.9±0.83,各组比较有显著差异(P<0.05或P<0.01)。②轻度和重度I UGR组血清GH、IGF-1、IGFBP-3、瘦素浓度(μg/L)分别为5.82±1.02和8.67±2.07,9.96±2.19和14.56±3.87,77.48±20.51和99.13±7.16,2.61±0.63和3.31±0.51,两组比较差异均有显著性(P<0.01)。【结论】新生儿血清GH、IGF-1、IGFBP-3、瘦素浓度水平与胎儿生长发育有密切关系,是调节胎儿宫内生长发育的重要因素。     

胰岛素样生长因子-1和表皮生长因子在窒息后新生儿血中水平的研究

目的:观察胰岛素样生长因子-1(IGF-1)、表皮生长因子(EGF)在窒息后新生儿血中的变化,探讨出生窒息对新生儿胃肠激素的影响。方法:用放射免疫分析法(RIA),测定40例窒息新生儿和30例正常足月新生儿出生后1d、3d、7d血中IGF-1、EGF的水平变化。结果:窒息新生儿血中IGF-1、EGF均比正常对照组显著下降(P<0·01);窒息后新生儿恢复期IGF-1、EGF升高。结论:窒息后新生儿血中IGF-1、EGF的水平下降,表明窒息新生儿胃肠激素水平异常,可能是造成患儿消化功能紊乱的因素之一。     

先天性甲状腺功能减低症治疗前后TSH、FT4、IGF-1水平的变化及与体格生长的关系

目的 了解先天性甲状腺功能减低症(congenitial hypothyroidism,CH)患儿经左甲状腺素钠替代治疗前后血清中胰岛素样生长因子-1(IGF-1)、促甲状腺激素(thyroid stimulating hormone,TSH)和游离甲状腺素(free thyroxine,FT4) 水平的变化,并分析这些指标对CH患儿体格发育的影响。 方法 采集未经治疗的27例CH新生儿和21例治疗后的CH幼儿,30例健康新生儿和30例健康幼儿(作为对照组)的外周静脉血,采用化学发光法测定各组TSH、FT4和IGF-l水平,测量各组体重、身长。结果 CH新生儿组与健康新生儿组相比,血清IGF-1、TSH、FT4水平显著降低(P<0.05)。经一元线性相关分析,CH新生儿IGF-1水平与TSH、FT4、出生体重(body weight,BW)、出生身长(body length,BL)均无明显相关性(P>0.05)。BW、BL与TSH负相关,与FT4正相关。经规范L-T4替代治疗后的CH幼儿组与健康幼儿组相比IGF-1、TSH和FT4水平差异均无统计学意义,两组的体重及身长差异无统计学意义。 结论TSH和FT4可能在 CH胎儿期的体格生长中起一定作用。经L-T4替代治疗后TSH、FT4和IGF-1水平升高,这可能是保证CH治疗后正常生长的因素之一。     

瘦素、胰岛素样生长因子-1和胰岛素样生长因子结合蛋白-3在绝经后骨质疏松患者血清中的表达及意义

目的观察瘦素、胰岛素生长因子-1(IGF-1)和胰岛素样生长因子结合蛋白-3(IGFBP-3)在绝经后骨质疏松(PMOP)患者血清中的表达,并探讨其临床意义。方法 60例PMOP患者根据是否伴随骨折分为无骨折组(34例)和伴骨折组(26例),同期选择40例未发生PMOP的绝经后妇女作为对照组,采用ELISA法检测各组血清瘦素、IGF-1、IGFBP-3表达水平,采用骨密度(BMD)仪检测各组腰椎(L1~L4)、股骨颈、Wards三角部位的BMD,比较各组差异性并分析血清瘦素、IGF-1、IGFBP-3与BMD的相关性关系。结果观察组血清瘦素、IGF-1和IGFBP-3表达水平及BMD均明显低于对照组(P0.05);PMOP伴骨折组患者血清瘦素、IGF-1、IGFBP-3表达水平及BMD均明显低于PMOP无骨折组(P0.05);血清瘦素、IGF-1、IGFBP-3三者之间,及其与BMD均呈正相关性关系(P0.05)。结论血清瘦素、IGF-1、IGFBP-3可作为早期诊断PMOP和评估其严重程度的敏感性实验室指标。     

阻塞性睡眠呼吸暂停低通气综合征儿童血清生长因子表达的影响因素分析

目的 分析阻塞性睡眠呼吸暂停低通气综合征(OSAHS)患儿血清胰岛素样生长因子-1(IGF-1)、胰岛素样生长因子结合蛋白-3(IGFBP-3)水平的变化及其影响因素。方法 纳入2012年7月-2015年7月在昆明市儿童医院住院的3~6岁220例OSAHS患儿和40例非睡眠呼吸障碍患儿。按呼吸暂停低通气指数(AHI)将OSAHS患儿分为轻度、中度、重度OSAHS组。检测所有儿童血清IGF-1、IGFBP-3水平,体重指数(BMI)、身高及体重,比较各组间的差异,并采用多元逐步回归分析探讨影响患儿血清IGF-1、IGFBP-3水平的因素。结果 重度OSAHS组血清IGF-1水平[(121.86±36.47)μg/L]显著低于对照组[(149.44±31.44)μg/L]、轻度OSAHS组[(147.63±26.83)μg/L]和中度OSAHS组[(142.11±34.50)μg/L](P均＜0.05),重度OSAHS组身高显著低于对照组(102.64±5.95)cm vs(105.22±6.03) cm,P＜0.05)。血清IGFBP-3水平、BMI和体重在各组间差异无统计学意义(P均＞0.05)。经多元逐步回归分析结果显示OSAHS组的血清IGF-1、IGFBP-3水平受年龄、平均最低血氧饱和度(LSaO₂)的影响。结论 OSAHS患儿生长发育迟缓可能与血清IGF-1水平降低有关,缺氧是影响OSAHS患儿血清IGF-1水平变化的因素。     

Effects of alcohol on insulin-like growth factor I and insulin-like growth factor binding protein 3 in postmenopausal women

BACKGROUND: Increased circulating insulin-like growth factor I (IGF-I) concentrations, frequently adjusted for IGF binding protein 3 (IGFBP-3), have been associated with increased risk of several types of cancer, including colon, prostate, and breast. Studies have suggested that alcohol may affect IGF-I or IGFBP-3; however, controlled feeding studies to assess alcohol's effects on IGF-I or IGFBP-3 have not been conducted. OBJECTIVE: To determine whether chronic, moderate alcohol intake affects serum IGF-I or IGFBP-3 concentrations, we performed a controlled, crossover feeding study. DESIGN: Fifty-three postmenopausal women were randomly assigned to consume 0 g (control), 15 g (one drink), or 30 g (2 drinks) alcohol daily for 8 wk and were rotated through the other 2 intake levels in random order. All foods and beverages were provided during the intervention. Individuals were monitored and calories adjusted to maintain constant weight, and serum was collected at the end of each diet period. RESULTS: Compared with the effects of 0 g alcohol/d, IGF-I concentrations were nearly unchanged by 15 g alcohol/d (0.8%; 95% CI: -3.2%, 3.5%) but decreased significantly by 4.9% (95% CI: -8.0%, -1.6%) with 30 g alcohol/d. IGFBP-3 concentrations significantly increased by 3.0% (95% CI: 0.4%, 5.6%) with 15 g alcohol/d but did not increase significantly with 30 g/d (1.8%; 95% CI: -0.9%, 4.5%). CONCLUSIONS: To our knowledge, this is the first published controlled diet study to find that in postmenopausal women, when weight is kept constant, alcohol consumption reduces the amount of serum IGF-I potentially available for receptor binding. These findings suggest that the effect of alcohol intake should be considered in studies of IGF-I, IGFBP-3, and cancer in postmenopausal women.     

Anthropometric and behavioral correlates of insulin-like growth factor I and insulin-like growth factor binding protein 3 in middle-aged Japanese men

High levels of plasma insulin-like growth factor I (IGF-I) and low levels of insulin-like growth factor binding protein 3 (IGFBP-3) have been related to increased risk of several cancers. Little is known about the behavioral determinants of these biologic markers. The authors examined the relation of anthropometric and behavioral factors to plasma concentrations of IGF-I and IGFBP-3 in a cross-sectional study of 616 Japanese men aged 45-55 years in 1995-1996. In univariate analyses, body mass index was strongly, positively associated with both IGF-I and IGFBP-3. The waist/hip ratio was also linearly related to IGF-I and IGFBP-3 up to the third quartile level. Height was weakly, positively associated with IGF-I and IGFBP-3. Smoking was inversely associated with IGF-I and IGFBP-3. Alcohol use was associated inversely with IGF-I and positively with IGFBP-3. Neither IGF-I nor IGFBP-3 was related to physical activity. Results of the multivariate analysis were essentially the same as those of the univariate analyses. The findings regarding body mass index are in contrast to those of previous studies showing null or inverse associations, and they suggest that the relation of body mass index to IGF-I or IGFBP-3 may vary among populations. The study also indicates that smoking and alcohol use might affect plasma IGF-I and IGFBP-3.     

Body size in early life and adult levels of insulin-like growth factor 1 and insulin-like growth factor binding protein 3

Body size in early life has been associated with breast cancer risk. This may be partly mediated through the insulin-like growth factor (IGF) pathway. The authors assessed whether birth weight, body fatness at ages 5 and 10 years, and body mass index (BMI; weight (kg)/height (m)(2)) at age 18 years were associated with plasma concentrations of insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 3 in 6,520 women aged 32-70 years at blood draw from the Nurses' Health Study (1990-2006) and Nurses' Health Study II (1997-2005). Birth weight, body fatness in childhood, and BMI at age 18 years were inversely associated with adult IGF-1 levels. For example, IGF-1 levels were 11.9% lower in women who reported being heaviest at age 10 years than in those who were leanest at age 10 (P-trend < 0.0001). Further, women who reported their birth weight as ≥10 pounds (≥4.5 kg) (vs. <5.5 pounds (<2.5 kg)) had 7.9% lower IGF-1 levels (P-trend = 0.002). Women whose BMI at age 18 years was ≥30 (vs. <20) had 14.1% lower IGF-1 levels (P-trend < 0.0001). Similar inverse associations were observed for insulin-like growth factor binding protein 3. These observations did not vary by adult BMI or menopausal status at blood draw. These findings suggest that altered IGF-1 levels in adulthood may be a mechanism through which early-life body size influences subsequent breast cancer risk.     

Enterotrophic effect of insulin-like growth factor-I but not growth hormone and localized expression of insulin-like growth factor-I, insulin-like growth factor binding protein-3 and -5 mRNAs in jejunum of parenterally fed rats

BACKGROUND: Administration of insulin-like growth factor (IGF)-I, but not growth hormone (GH), stimulates mucosal hyperplasia in surgically stressed rats with intestinal atrophy induced by hypocaloric total parenteral nutrition (TPN). Our aim was to characterize the basis for this disparity in enterotrophic action by assessing the relationships between stimulation of intestinal growth, nutritional adequacy, and localization of expression of IGF-I, insulin-like growth factor binding protein (IGFBP)-3 and IGFBP-5 mRNAs in jejunum. METHODS: Rats were maintained with TPN for 8 days and treated with IGF-I or GH and adequate nutrition for 5 days after recovery from surgery. Jejunal mass, morphology, and sucrase activity were assessed. Localization of expression of IGF-I, IGFBP-3, and IGFBP-5 mRNAs in jejunum was accomplished by in situ hybridization. RESULTS: Serum IGF-I and body weight gain were significantly increased by IGF-I or GH. Jejunal mucosal dry mass, morphology, and sucrase activity were improved with IGF-I but not GH. There were no differences in IGF-I mRNA. IGFBP-3 mRNA was localized in the lamina propria of the villi. IGF-I or GH stimulated IGFBP-3 expression. IGF-I strongly stimulated IGFBP-5 expression in the lamina propria and the muscularis and induced a twofold increase in IGFBP-5 mRNA based on RNase protection assay of intact jejunum total RNA. GH induced a modest increase in IGFBP-5 expression in the muscularis with no effect on intact jejunum total RNA. CONCLUSIONS: The GH resistance observed in the jejunal mucosa of TPN rats cannot be fully explained by inadequate nutrition. The expression of IGFBP-5 in the lamina propria suggests it may modulate the enterotrophic action of exogeneous IGF-I.     

学龄前肥胖儿童血清IGF-Ⅰ、IGF-BP_3与其他激素相互关系的研究

【目的】研究学龄前肥胖儿童血清胰岛素样生长因子-Ⅰ（IGF-Ⅰ）、胰岛素样生长因子结合蛋白-3（IGF-BP3）与瘦素（Leptin）、胰岛素（Ins）、雌二醇（E2）及睾酮（T）的相互关系,探讨IGF-I在肥胖发病机制中的作用,为肥胖儿童的早期干预提供理论依据。【方法】对122例学龄前肥胖儿童及61例正常儿童血清IGF-Ⅰ、IGF-BP3、Leptin、Ins、E2和T水平进行测定,并分析IGF-Ⅰ、IGF-BP3与其他激素的相互关系。【结果】学龄前肥胖儿童血清IGF-Ⅰ、IGF-BP3、Leptin、Ins和E2水平明显高于对照组（P值均〈0.001）,两组间睾酮水平差异无显著性（P〉0.05）;血清IGF-Ⅰ、IGF-BP3与Leptin、Ins、E2及睾酮水平显著正相关（P值均〈0.01）,且Leptin与Ins、E2水平显著正相关（P值均〈0.001）;多元线性回归分析显示IGF-BP3、Ins和E2是影响IGF-Ⅰ的重要因素。【结论】学龄前肥胖儿童IGF-Ⅰ、Leptin和Ins在调节机体能量代谢过程中不仅作为独立的外周因子发挥作用,同时提示IGF-Ⅰ对儿童生长发育以及性发育的调控受Leptin、Ins及性激素多种激素水平的共同影响,IGF-Ⅰ是儿童肥胖又一敏感检测指标。     

学龄前肥胖儿童血清IGF-I、IGF-BP3与其他激素相互关系的研究

[目的]研究学龄前肥胖儿童血清胰岛素样生长因子-I(IGF-I)、胰岛素样生长因子结合蛋白-3(IGF-BP3)与瘦素(Leptin)、胰岛素(Ins)、雌二醇(E2)及睾酮(T)的相互关系,探讨IGF-I在肥胖发病机制中的作用,为肥胖儿童的早期干预提供理论依据.[方法]对122例学龄前肥胖儿童及61例正常儿童血清IGF-I、IGF-BP3、LEI、in、Ins、E2和T水平进行测定,并分析IGF-I、IGF-BP3与其他激素的相互关系.[结果]学龄前肥胖儿童血清IGF-I、IGF-BP3、Lepfin、Ins和E2水平明显高于对照组(P值均＜O.001),两组间睾酮水平差异无显著性(P>O.05);血清IGF-I、IGF-BP3与Leptin、Ins、E2及睾酮水平显著正相关(P值均＜0.01),且Leptin与Ins、E2水平显著正相关(P值均＜0.001);多元线性回归分析显示IGF-BP3、Ins和E2是影响IGF-I的重要因素.[结论]学龄前肥胖儿童IGF-I、Leptin和Ins在调节机体能量代谢过程中不仅作为独立的外周因子发挥作用,同时提示IGF-I对儿童生长发育以及性发育的调控受Leptin、Ins及性激素多种激素水平的共同影响,IGF-I是儿童肥胖又一敏感检测指标.     

Effect of lycopene supplementation on insulin-like growth factor-1 and insulin-like growth factor binding protein-3: a double-blind, placebo-controlled trial

OBJECTIVE: Studies have suggested a link between lycopene and insulin-like growth factor-1 (IGF-1). The aim of this study was to test the effect of lycopene supplementation on IGF-1 and binding protein-3 (IGFBP-3) status in healthy male volunteers. DESIGN, SETTING, SUBJECTS AND INTERVENTION: This was a 4 week randomized, double-blind, placebo-controlled study of lycopene supplementation (15 mg/day) in healthy male volunteers (n=20). Fasting blood samples were collected at baseline and after 4 weeks. Samples were analysed for lycopene by high-performance liquid chromatography (HPLC) and IGF-1 and IGFBP-3 by enzyme-linked immunosorbent assay (ELISA). Changes in end points from baseline were compared in those who received placebo versus those who received the lycopene supplement. RESULTS: Median change in lycopene from baseline (post-supplement - baseline) was higher in subjects in the intervention than those on placebo (lycopene group 0.29 (0.09, 0.46); placebo group 0.03 (-0.11, 0.08) micromol/l; median (25th, 75th percentiles), P<0.01). There was no difference in median change in IGF-1 concentrations (lycopene group -0.6 (-2.6, 1.9); placebo group -1.15 (-2.88, 0.95) nmol/l, P=0.52), or median change in IGFBP-3 concentrations (lycopene group 245 (-109, 484); placebo group 101 (-34, 234) nmol/l, P=0.55) between intervention and control groups. Change in lycopene concentration was associated with the change in IGFBP-3 in the intervention group (r=0.78; P=0.008; n=10). CONCLUSIONS: Lycopene supplementation in healthy male subjects has no effect on IGF-1 or IGFBP-3 concentrations in a healthy male population. However, the association between change in lycopene concentration and change in IGFBP-3 in the intervention group suggests a potential effect of lycopene supplementation on IGFBP-3.     

血清IGF-1、IGFBP-3水平和大肠癌关系的Meta分析

目的综合评价血清胰岛素样生长因子-1(IGF-1)、胰岛素样生长因子结合蛋白-3(IGFBP-3)水平和大肠癌的关系。方法利用Meta分析法对6篇关于血清IGF-1、IGFBP-3水平与大肠癌关系的研究文献进行定量综合分析。结果对于IGF-1，合并OR=1．56(95％CI：1．14～2．13)；按实验方法不同分层，间接酶联免疫吸附试验(ELISA)合并OR=1．92(95％CI：1．26～2．93)，IRMA法合并OR=1．23(95％CI：0．78～1．94)；对于IGFBP-3，合并OR=0．78(95％CJ：0．43～1．44)；按实验方法不同分层，ELISA法合并OR=0．46(95％CI：0．29～0．74)，免疫放射测定法(IRMA)合并OR=1．44(95％CI：0．93～2．23)。结论血清IGF-1高水平为大肠癌的独立危险因子，IGFBP-3与大肠癌的关联不具有统计学意义；IGFBP-3与大肠癌关系的各研究之间异质性是由实验方法不同而引起，但该结论尚需大样本并同时进行两种方法的测量证实。